Content-Transfer-Encoding: |
7bit |
Sender: |
|
Subject: |
|
From: |
|
Date: |
Tue, 20 Mar 2001 06:30:05 EST |
Content-Type: |
text/plain; charset="US-ASCII" |
MIME-Version: |
1.0 |
Reply-To: |
|
Parts/Attachments: |
|
|
For those who have a difficult time believeing that Martek is genetically
engineering the microalgae (DHA) I have one of the company's information
releases dated 1997 by the menu but dated 1998 in the release itself.
Valerie W. McClain, IBCLC
http://www.martekbio.com/980309.html
COLUMBIA, MD, MARCH 9, 1998 -- Martek Biosciences Corporation (NASDAQ: MATK)
today announced that the National Science Foundation (NSF) has awarded the
Company a Phase II Small Business Innovation Research (SBIR) grant to develop
technology for the genetic transformation of microalgae. This research could
set the stage for the use of molecular technology in the development of
commercially important products from microalgae. Martek will be assisted by
the Carnegie Institution of Washington, Plant Biology Division.
"This NSF grant should help advance microalgal technology," said Henry
Linsert, Jr., Martek's Chairman and CEO. "This is not only important to
science but also future commercial products and processes."
***********************************************
The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html
|
|
|